HC Wainwright Estimates Evotec’s Q1 Earnings (NASDAQ:EVO)

Evotec AG (NASDAQ:EVO) – Analysts at HC Wainwright reduced their Q1 2027 earnings estimates for shares of Evotec in a research report issued to clients and investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous estimate of $0.02. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.03 EPS and Q4 2027 earnings at $0.04 EPS.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Wednesday. Weiss Ratings upgraded shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Finally, Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

Evotec Stock Performance

Shares of EVO stock opened at $1.96 on Thursday. The company has a quick ratio of 1.60, a current ratio of 1.68 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $2.75 and a two-hundred day moving average of $3.01. Evotec has a 1-year low of $1.95 and a 1-year high of $4.42.

Institutional Trading of Evotec

Hedge funds have recently made changes to their positions in the business. Apollon Wealth Management LLC acquired a new position in shares of Evotec in the first quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its holdings in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after buying an additional 4,600 shares in the last quarter. Bank of America Corp DE boosted its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the period. Marshall Wace LLP purchased a new position in Evotec in the 4th quarter valued at approximately $40,000. Finally, XTX Topco Ltd acquired a new position in shares of Evotec in the second quarter worth $66,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec News Summary

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Evotec AG and kept its $4.00 price target, signaling some confidence in longer-term upside.
• Neutral Sentiment: Analysts still expect Evotec to remain loss-making in the near term, with forecast EPS revisions showing only a gradual path toward profitability. Evotec AG stock page
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to ($0.04) from ($0.01), implying weaker-than-expected near-term earnings momentum.
• Negative Sentiment: The firm also lowered its Q4 2026 EPS forecast to ($0.02), reduced FY2026 EPS to ($0.31), and trimmed FY2027 EPS to $0.07, reinforcing concerns about slower earnings recovery.
• Negative Sentiment: Separately, Berenberg Bank downgraded Evotec from Buy to Hold, which likely added to the stock’s weakness by signaling less conviction in the near-term setup.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.